ZURICH, Dec 3 (Reuters) - Roche's newly acquired
subsidiary TIB Molbiol has developed three new tests kits to
detect mutations present in the new COVID-19 Omicron variant,
Roche said on Friday.
"The teams at TIB Molbiol have worked around the clock since
the new variant emerged, and today we are able to offer a test
that can specifically identify the novel B.1.1.529 Omicron
SARS-CoV-2 variant to help better understand its spread and
behaviour," Thomas Schinecker, head of Roche Diagnostics, said
in a statement.
Roche acquired Berlin-based TIB Molbiol on Dec. 1 to expand
its PCR-test portfolio to combat new infectious diseases.
(Reporting by Brenna Hughes Neghaiwi
Editing by Paul Carrel)